Dr Jennette Sakoff

Conjoint Associate Professor

School of Environmental and Life Sciences (Chemistry)

Career Summary

Biography

Research Expertise
Dr Sakoff is an experienced cell biologist and Chief Hospital Scientist in the Department of Medical Oncology at the Calvary Mater Newcastle Hospital. Dr Sakoff is the leader of the Experimental Therapeutics Group. She has made significant contributions to cancer research particularly in the development of small molecules for the treatment of cancer. Areas of expertise includes cell culture, drug screening, cell biology, proteomics, cell cycle analysis, drug combination studies, clinical toxicity.

Teaching Expertise
Selected lectures in drug development.

Qualifications

  • PhD, University of Newcastle

Keywords

  • Breast Cancer
  • Cancer
  • Chemotherapy
  • Drug Development
  • Dynamin
  • Glioblastoma
  • PP2A

Professional Experience

Professional appointment

Dates Title Organisation / Department
1/1/2016 -  Chair of Calvary Mater Newcastle Research Committee Calvary Mater Newcastle
Australia
1/2/1996 -  Chief Hospital Scientist Calvary Mater Newcastle Hospital
Medical Oncology
Australia

Awards

Research Award

Year Award
2000 Young medical researcher of the year
Unknown
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Conference (35 outputs)

Year Citation Altmetrics Link
2020 Sakoff J, Gilbert J, Baker J, McCluskey A, 'The aryl hydrocarbon receptor pathway and breast cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
Co-authors Jennifer R Baker, Adam Mccluskey
2019 Sakoff J, Fay M, Lynam J, Gilbert J, 'High Levels of the Protein Receptor EphA2 in the Blood of Brain Cancer Patients Undergoing Treatment for their Disease Predicts for Shorter Survival', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 15, 28-29 (2019)
Co-authors Michael Fay
2019 Garg M, Galettis P, Sakoff J, Lynam J, Martin J, Ackland S, 'A Simple Rapid HPLC Method for the Simultaneous Measurement of Temozolomide and Its Metabolite Levels in Glioblastoma Cancer Patients Plasma Samples', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2019)
Co-authors Stephen Ackland, Jenniferh Martin
2018 Scorgie F, Gilbert J, Garg M, Sakoff J, Lincz L, 'What is the Best Way to Measure Blood Cell Mean Telomere Length?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Lisa Lincz
2018 Tamessar C, Garg M, Sakoff J, Lincz L, Xavier A, Talseth-Palmer B, Ackland S, 'Using Genomics and Pharmacokinetics to Predict 5FU Toxicity', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 14, 31-32 (2018)
Co-authors Alexandre Xavier, Stephen Ackland, Lisa Lincz, Bente Talseth-Palmer
2017 Sakoff J, Gilbert J, Tarleton M, McCluskey A, 'Phenylacrylonitrile-Based Small Molecules Utilize the Aryl-Hydrocarbon Receptor Pathway (AhR) to Selectively Kill Breast Cancer Cells', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Co-authors Adam Mccluskey
2016 Sakoff J, Gilbert J, Tarleton M, Trinh TN, De Uillius G, McCluskey A, 'HI-JACKING THE ARYL-HYDROCARBON RECEPTOR PATHWAY FOR THE TREATMENT OF BREAST CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 12, 8-8 (2016)
Co-authors Trieu N Trinh, Adam Mccluskey
2016 Sakoff JA, Gilbert J, De Luliis G, McCluskey A, 'A novel class of phenylacrylonitrile-based small molecules selectively induce double-strand DNA damage in breast cancer cells', CANCER RESEARCH, New Orleans, LA (2016)
DOI 10.1158/1538-7445.AM2016-4803
Co-authors Adam Mccluskey
2016 Blanchard G, Bilsborough R, Cook D, Gilbert J, Lombard J, Nordman I, et al., 'A CELL BASED IN VITRO MODEL IN ASSESSING THE EFFECTIVENESS OF NAIL LACQUER IN PROTECTING AGAINST UV PENETRATION: A PRECLINICAL MODEL', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
2015 Fay M, Sakoff J, Martin J, Rose S, Crozier S, Boyd A, Dittman K, Rodemann H-P, 'EPHA2 ANTIBODY INCREASES SENSITIVITY OF U87 GLIOBLASTOMA CELLS TO IRRADIATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 11, 2-2 (2015) [E3]
Co-authors Michael Fay, Jenniferh Martin
2015 Ackland SP, Sakoff JA, Johnson C, Garg MB, 'OPTIMAL TDM AND PHARMACODYNAMICS OF MITOTANE IN ADRENOCORTICAL CANCER (ACC) IN CHILDREN AND ADULTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Stephen Ackland
2015 Milioli HH, Tishchenko I, Riveros C, Sakoff J, Berretta R, Moscato P, 'Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making', ANNALS OF ONCOLOGY, Brussels, BELGIUM (2015) [E3]
DOI 10.1093/annonc/mdv121.8
Co-authors Regina Berretta, Pablo Moscato, Carlos Riveros
2015 Garg M, Galettis P, Goulooze S, Clingan P, Ranson M, Sakoff J, et al., 'THERAPEUTIC DRUG MONITORING FOR CANCER PATIENTS RECEIVING CHEMOTHERAPY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Stephen Ackland, Jenniferh Martin
2015 Garg M, Ackland S, McCluskey A, Scorgie F, Lincz L, McCluskey S, et al., 'THE PROTEIN PHOSPHATASE INHIBITOR CANTHARIDIN, POTENTIATES THE EFFECT OF ALL-TRANS RETINOIC ACID IN ACUTE PROMYLOCYTIC LEUKEMIA CELLS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Lisa Lincz, Adam Mccluskey, Stephen Ackland
2015 Bond D, Turner A, Richmond R, Sadeqzadeh E, Vuong Q, Bhuyan D, Rifai Y, Chalmers A, van Altena I, Gaston T, Bowyer M, Brzozowski J, Jankowski H, Weidenhofer J, Sakoff J, Thuong PT, Ha DT, Khoi NM, Scarlett C, 'THE SEARCH FOR NOVEL TREATMENT AGENTS FOR PANCREATIC CANCER: TALES FROM THE LAND AND SEA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 11, 19-19 (2015) [E3]
Co-authors Vanquan Vuong, Judith Weidenhofer, Michael Bowyer, Troy Gaston, C Scarlett, Ian Vanaltena, Danielle Bond, Anita Chalmers
2014 Sakoff J, Gilbert J, McCluskey A, 'Small molecules selectively targeting breast cancer cells', EUROPEAN JOURNAL OF CANCER, European Org Res & Treatment Canc, Barcelona, SPAIN (2014) [E3]
DOI 10.1016/S0959-8049(14)70226-6
Citations Web of Science - 1
Co-authors Adam Mccluskey
2014 Ackland SP, Garg MB, Tacon L, Johnson C, Sakoff J, 'Mitotane pharmacodynamics in adrenocortical cancer in children and adults.', JOURNAL OF CLINICAL ONCOLOGY, Chicago, IL (2014)
DOI 10.1200/jco.2014.32.15_suppl.e13532
Co-authors Stephen Ackland
2014 Garg MB, Sakoff JA, Johnson C, Bonaventura A, Ackland SP, 'CLINICAL STUDY OF MITOTANE PHARMACODYNAMICS IN ADRENOCORTICAL CANCER IN CHILDREN AND ADULTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Stephen Ackland
2014 Gilbert J, Dun MD, De Iuliis GN, McCluskey A, Sakoff JA, 'SELECTIVELY TARGETING BREAST CANCER CELLS VIA CHECKPOINT ACTIVATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, 13-13 (2014) [E3]
Co-authors Matt Dun, Adam Mccluskey, Geoffry DeiuliIs
2014 Gilbert J, McCluskey A, Sakoff JA, 'ENHANCING RADIATION EFFECTS FOR THE TREATMENT OF BRAIN CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Adam Mccluskey
2014 Prawira A, Garg MB, Sakoff JA, Lincz LF, Adler K, Scorgie FE, Ackland SP, 'FACTORS PREDICTING RESPONSE AND SURVIVAL IN COLORECTAL CANCER PATIENTS RECEIVING ADJUVANT 5-FLUOROURACIL CHEMOTHERAPY: 10-YEAR FOLLOW-UP OF A PROSPECTIVE PATIENT COHORT', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Lisa Lincz, Stephen Ackland
2013 Sakoff JA, Gilbert J, Tarleton M, Robertson M, McCluskey A, 'New small molecules targeting breast cancer', INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013) [E3]
Co-authors Adam Mccluskey
2012 Sakoff JA, Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, 'Predicting chemotherapy-induced toxicity in cancer patients from peripheral blood telomere length', European Journal of Cancer, Barcelona, Spain (2012) [E3]
Co-authors Lisa Lincz, Stephen Ackland
2010 Garg M, Sakoff JA, Ackland S, 'A simple HPLC method to measure plasma mitotane and its two main metabolites in adrenocortical cancer patients', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authors Stephen Ackland
2010 Joshi S, Gaddipatti S, Gilbert J, Smith CM, Gordon CP, Sakoff JA, et al., 'Dynamin inhibition: A new therapeutic approach for the treatment of cancer', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authors Adam Mccluskey
2010 Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Telomere length in peripheral blood mononuclear cells (PBMNC) predicts for leukopenia, neutropenia and mucositis in colorectal cancer patients treated with 5FU', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authors Stephen Ackland, Lisa Lincz
2010 Sakoff JA, Garg M, Adler K, Scorgie FE, Lincz L, Ackland S, 'Short telomeres in PBMNC predicts for haematological toxicity in colorectal cancer patients treated with 5FU', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authors Stephen Ackland, Lisa Lincz
2010 Chircop M, Perera S, Ma MPC, Lau H, Gilbert J, Jones NC, et al., 'Dynole 34-2 is a potent inhibitor of dynamin that induces cell death following cytokinesis failure and suppresses glioblastoma tumour growth in vivo', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
Co-authors Adam Mccluskey
2002 Sakoff JA, Ackland SP, Garg MB, Walkom CC, McCluskey A, 'Protein phosphatase 2A, a novel and unexplored anticancer target', EUROPEAN JOURNAL OF CANCER, FRANKFURT, GERMANY (2002)
Co-authors Stephen Ackland, Adam Mccluskey, Cecilia Russell
1996 Sakoff JA, Murdoch RN, 'Uterine decidualization and calcium ion alterations in pseudopregnant mice' (1996) [E1]
1995 Sakoff JA, Dunstan RH, Murdoch RN, 'The n-3 and n-6 fatty acid profile of uterine tissue following the Concanavalin A induced decidual cell reaction in mice', Unknown, Unknown (1995) [E1]
1995 Sakoff JA, Dunstan RH, Murdoch RN, 'Alterations in uterine saturated fatty acids and cholesterol accompany induction of decidualization in pseudopregnant mice' (1995) [E1]
1994 Sakoff JA, Murdoch RN, 'The period of uterine receptivity in the pseudopregnant Quackenbush Special mouse as defined by the deciduogenic lectin, Concanavalin A' (1994) [E1]
1993 Sakoff JA, Murdoch RN, Dunstan RH, 'Changes in the poly-unsaturated fatty acid composition of the uterus during induction of the decidual cell reaction in pseudopregnant mice', Changes in the poly-unsaturated fatty acid composition of the uterus during induction of the decidual cell reaction in pseudopregnant mice, Unknown (1993) [E1]
1991 Sakoff J, Murdoch RN, 'Uterine decidualization and calcium ion alterations in pseudopregnant mice' (1991) [E1]
Show 32 more conferences

Journal article (124 outputs)

Year Citation Altmetrics Link
2025 Rashid F, Gordon CP, Sakoff JA, Gilbert J, García F, Aldrich-Wright JR, 'Effective and scalable mechanochemical synthesis of platinum(ii) heteroleptic anticancer complexes', Green Chemistry, 27, 10145-10152 (2025) [C1]
DOI 10.1039/d5gc02781k
2025 Jurisinec A, Sakoff J, Gilbert J, Gordon CP, Aldrich-Wright JR, 'Coupling approaches for [Pt(1,10-phenanthroline)(1S,2S-diamminocyclohexane)dihydroxide]2¿ using hydrazone and oxime ligation', Dalton Transactions, 54, 7105-7114 (2025) [C1]
DOI 10.1039/d5dt00303b
2025 Sakoff JA, Amin MK, Robertson MJ, Chiew B, Tarleton M, Young KA, Venn-Brown B, Chau N, Gordon CP, Chircop M, Paula S, Jones NC, O'Brien TJ, Robinson PJ, McCluskey A, 'Dynole-Based Dynamin Inhibitors as Novel Cytotoxic Agents', Chemistryselect, 10 (2025) [C1]

Dynamin plays a crucial role in mitosis, and dynamin inhibition broadly correlates with cytotoxicity. Dynole 34¿2, dynamin inhibitor, is highly cytotoxic, but its poor ... [more]

Dynamin plays a crucial role in mitosis, and dynamin inhibition broadly correlates with cytotoxicity. Dynole 34¿2, dynamin inhibitor, is highly cytotoxic, but its poor drug-like properties limit its in vivo development. Three focused libraries of dynole-based dynamin inhibitors were synthesized enhance their druglike properties while maintaining their dynamin inhibition and cytotoxicity. Iterative modifications were undertaken to probe the effects of changes to the cyanoacrylamide linker amide, alkyl chain moieties, the N-propyl-N,N-dimethylamino moiety and the indole core. These compounds were screened against: HT29 and SW480 (colon), SMA (spontaneous murine astrocytoma), MCF-7 (breast), BE2-C (glioblastoma), SJ-G2 (neuroblastoma), MIA (pancreas), A2780 (ovarian), A431 (skin), H460 (lung), U87 (glioblastoma) and DU145 (prostate) cell lines to reveal a good correlation between dynamin inhibition and cytotoxicity. High potency against brain cancer cell lines was observed. The most dynamin active compounds returned average GI50 values of 2.26 and 1.5¿µM across the cell lines examined. The most active compound against 4 brain cancer cell lines averaged a GI50 value of 4.7¿µM; 10-fold improved over the gold standard for glioblastoma treatment; temozolomide. Importantly, this maintained a tPSA of 24.8Å2 and cLogP of 4.11; appropriate for blood brain barrier penetration. This active analogue in this series was (Z)-2-(3,4-dichlorophenyl)-3-(1-(3-(dimethylamino)propyl)-1H-pyrrol-3-yl)acrylonitrile (34).

DOI 10.1002/slct.202405049
Co-authors Adam Mccluskey
2025 Prichard K, Yamamoto S, Shimadate Y, Yoshimura K, Bartholomew B, Gilbert J, Sakoff J, Nash R, Kato A, Simone M, 'Borylated Five-Membered Ring Iminosugars: Synthesis, Spectroscopic Analysis, and Biological Evaluation for Glycosidase Inhibition and Anticancer Properties for Application in Boron Neutron Capture Therapy (BNCT)—Part 1', Pharmaceuticals, 18 (2025) [C1]
DOI 10.3390/ph18091302
2024 Aputen AD, Elias MG, Gilbert J, Sakoff JA, Gordon CP, Scott KF, Aldrich-Wright JR, 'Platinum(IV) Prodrugs Incorporating an Indole-Based Derivative, 5-Benzyloxyindole-3-Acetic Acid in the Axial Position Exhibit Prominent Anticancer Activity', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 25 (2024) [C1]
DOI 10.3390/ijms25042181
Citations Scopus - 3Web of Science - 2
2024 O'Brien NS, Gilbert J, McCluskey A, Sakoff JA, '2,3-Dihydroquinazolin-4(1H)-ones and quinazolin-4(3H)-ones as broad-spectrum cytotoxic agents and their impact on tubulin polymerisation', RSC MEDICINAL CHEMISTRY, 15, 1686-1708 (2024) [C1]
DOI 10.1039/d3md00600j
Citations Scopus - 6Web of Science - 3
Co-authors Adam Mccluskey
2024 Prichard K, Chau N, Xue J, Krauss M, Sakoff JA, Gilbert J, Bahnik C, Muehlbauer M, Radetzki S, Robinson PJ, Haucke V, McCluskey A, 'Inhibition Clathrin Mediated Endocytosis: Pitstop 1 and Pitstop 2 Chimeras', CHEMMEDCHEM, 19 (2024) [C1]
DOI 10.1002/cmdc.202400253
Co-authors Adam Mccluskey
2024 Baker JR, Gilbert J, O'Brien NS, Russell CC, Mccluskey A, Sakoff JA, 'Next-generation of BBQ analogues that selectively target breast cancer', FRONTIERS IN CHEMISTRY, 12 (2024) [C1]
DOI 10.3389/fchem.2024.1396105
Co-authors Adam Mccluskey, Jennifer R Baker
2023 McGhie BS, Sakoff J, Gilbert J, Gordon CP, Aldrich-Wright JR, 'Synthesis and Characterisation of Platinum(II) Diaminocyclohexane Complexes with Pyridine Derivatives as Anticancer Agents', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (2023) [C1]
DOI 10.3390/ijms242417150
Citations Scopus - 4Web of Science - 1
2023 Sun J, Baker JR, Russell CC, Pham HNT, Goldsmith CD, Cossar PJ, Sakoff JA, Scarlett CJ, Mccluskey A, 'Novel piperazine-1,2,3-triazole leads for the potential treatment of pancreatic cancer', RSC MEDICINAL CHEMISTRY, 14, 2246-2267 (2023) [C1]
DOI 10.1039/d2md00289b
Citations Scopus - 2
Co-authors Adam Mccluskey, Jennifer R Baker, C Scarlett
2023 McGhie BS, Sakoff J, Gilbert J, Gordon CP, Aldrich-Wright JR, 'Synthesis and Characterisation of Fluorescent Novel Pt(II) Cyclometallated Complexes with Anticancer Activity', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24 (2023) [C1]
DOI 10.3390/ijms24098049
Citations Scopus - 4Web of Science - 3
2023 Aputen AD, Elias MG, Gilbert J, Sakoff JA, Gordon CP, Scott KF, Aldrich-Wright JR, 'Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents', CANCERS, 15 (2023) [C1]
DOI 10.3390/cancers15092460
Citations Scopus - 6Web of Science - 5
2022 Sun J, Ambrus JI, Baker JR, Russell CC, Cossar PJ, Sakoff JA, Scarlett CJ, McCluskey A, '3,5-Bis(trifluoromethyl)phenylsulfonamides, a novel pancreatic cancer active lead. Investigation of the terminal aromatic moiety', BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 61 (2022) [C1]
DOI 10.1016/j.bmcl.2022.128591
Citations Scopus - 4Web of Science - 4
Co-authors Cecilia Russell, Jennifer R Baker, Adam Mccluskey, C Scarlett
2022 Khoury A, Elias E, Mehanna S, Shebaby W, Deo KM, Mansour N, Khalil C, Sayyed K, Sakoff JA, Gilbert J, Daher CF, Gordon CP, Taleb RI, Aldrich-Wright JR, 'Novel Platinum(II) and Platinum(IV) Antitumor Agents that Exhibit Potent Cytotoxicity and Selectivity', JOURNAL OF MEDICINAL CHEMISTRY, 65, 16481-16493 (2022) [C1]
DOI 10.1021/acs.jmedchem.2c01310
Citations Scopus - 1Web of Science - 8
2022 Campkin DM, Shimadate Y, Bartholomew B, Bernhardt P, Nash RJ, Sakoff JA, Kato A, Simone M, 'Borylated 2,3,4,5-Tetrachlorophthalimide and Their 2,3,4,5-Tetrachlorobenzamide Analogues: Synthesis, Their Glycosidase Inhibition and Anticancer Properties in View to Boron Neutron Capture Therapy', MOLECULES, 27 (2022) [C1]
DOI 10.3390/molecules27113447
Citations Scopus - 9Web of Science - 6
2022 Aputen AD, Elias MG, Gilbert J, Sakoff JA, Gordon CP, Scott KF, Aldrich-Wright JR, 'Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates', MOLECULES, 27 (2022) [C1]
DOI 10.3390/molecules27207120
Citations Scopus - 9Web of Science - 8
2022 McGhie BS, Sakoff J, Gilbert J, Gordon CP, Aldrich-Wright JR, 'Novel Planar Pt(II) Cyclometallated Cytotoxic Complexes with G-Quadruplex Stabilisation and Luminescent Properties', International Journal of Molecular Sciences, 23 (2022) [C1]

Herein is described the development of a series of novel quadruplex DNA (QDNA)-stabilising cyclometallated square¿planar metal complexes (CMCs). Melting experiments usi... [more]

Herein is described the development of a series of novel quadruplex DNA (QDNA)-stabilising cyclometallated square¿planar metal complexes (CMCs). Melting experiments using quadruplex DNA (QDNA) demonstrated that interactions with the complexes increased the melting temperature by up to 19 °C. This QDNA stabilisation was determined in two of the major G-quadruplex structures formed in the human c-MYC promoter gene (c-MYC) and a human telomeric repeat sequence (H-Telo). The CMCs were found to stabilise H-telo more strongly than c-MYC, and the CMCs with the highest cytotoxic effect had a low¿moderate correlation between H-telo binding capacity and cytotoxicity (R2 values up to 10 times those of c-MYC). The melting experiments further revealed that the stabilisation effect was altered depending on whether the CMC was introduced before or after the formation of QDNA. All CMCs' GI50 values were comparable or better than cisplatin in human cancer cell lines HT29, U87, MCF-7, H460, A431, Du145, BE2-C, SJ-G2, MIA, and ADDP. Complexes 6, 7, and 9 were significantly more cytotoxic than cisplatin in all cell lines tested and had good to moderate selectivity indices, 1.7¿4.5 in MCF10A/MCF-7. The emission quantum yields were determined to be relatively high (up to 0.064), and emission occurred outside cellular autofluorescence, meaning CMC fluorescence is ideal for in vitro analyses.

DOI 10.3390/ijms231810469
Citations Scopus - 8
2022 Aputen AD, Elias MG, Gilbert J, Sakoff JA, Gordon CP, Scott KF, Aldrich-Wright JR, 'Potent Chlorambucil-Platinum(IV) Prodrugs', INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23 (2022) [C1]
DOI 10.3390/ijms231810471
Citations Scopus - 1Web of Science - 13
2022 Khoury A, Sakoff JA, Gilbert J, Scott KF, Karan S, Gordon CP, Aldrich-Wright JR, 'Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity', PHARMACEUTICS, 14 (2022) [C1]
DOI 10.3390/pharmaceutics14040787
Citations Scopus - 2Web of Science - 18
2022 Bjelosevic A, Sakoff J, Gilbert J, Zhang Y, McGhie B, Gordon C, Aldrich-Wright JR, 'Synthesis, characterisation and biological activity of the ruthenium(II) complexes of the N4-tetradentate (N4-TL), 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-diazahexane (picenBz2)', Journal of Inorganic Biochemistry, 226 (2022) [C1]
DOI 10.1016/j.jinorgbio.2021.111629
Citations Scopus - 1
2022 Ngoc MQP, Vuong QV, Sakoff JA, Bowyer MC, Van AL, Scarlett CJ, 'Determination of bioactive compounds, antioxidant and anticancer activities of Tuckeroo (Cupaniopsis anacardioides) fruits', 3 BIOTECH, 12 (2022) [C1]
DOI 10.1007/s13205-022-03314-z
Citations Scopus - 4Web of Science - 3
Co-authors Michael Bowyer, C Scarlett, Vanquan Vuong
2022 Odell LR, Chau N, Russell CC, Young KA, Gilbert J, Robinson PJ, Sakoff JA, McCluskey A, 'Pyrimidyn-Based Dynamin Inhibitors as Novel Cytotoxic Agents', CHEMMEDCHEM, 17 (2022) [C1]
DOI 10.1002/cmdc.202100560
Citations Scopus - 2
Co-authors Cecilia Russell, Adam Mccluskey
2022 Khoury A, Sakoff JA, Gilbert J, Karan S, Gordon CP, Aldrich-Wright JR, 'Potent Platinum(IV) Prodrugs That Incorporate a Biotin Moiety to Selectively Target Cancer Cells', PHARMACEUTICS, 14 (2022) [C1]
DOI 10.3390/pharmaceutics14122780
Citations Scopus - 1Web of Science - 11
2021 Baker JR, Russell CC, Gilbert J, McCluskey A, Sakoff JA, 'Amino alcohol acrylonitriles as broad spectrum and tumour selective cytotoxic agents', RSC MEDICINAL CHEMISTRY, 12, 929-+ (2021) [C1]
DOI 10.1039/d1md00021g
Citations Scopus - 1Web of Science - 12
Co-authors Jennifer R Baker, Adam Mccluskey, Cecilia Russell
2021 Baker JR, Pollard BL, Lin AJS, Gilbert J, Paula S, Zhu X, Sakoff JA, McCluskey A, 'Modelling and Phenotypic Screening of NAP-6 and 10-Cl-BBQ, AhR Ligands Displaying Selective Breast Cancer Cytotoxicity in Vitro', CHEMMEDCHEM, 16, 1499-1512 (2021) [C1]
DOI 10.1002/cmdc.202000721
Citations Scopus - 1Web of Science - 12
Co-authors Jennifer R Baker, Adam Mccluskey
2021 Sun J, Ambrus J, Russell CC, Baker JR, Cossar PJ, Pirinen MJ, Sakoff JA, Scarlett CJ, McCluskey A, 'Targeting the S100A2-p53 Interaction with a Series of 3,5-Bis(trifluoromethyl)benzene Sulfonamides: Synthesis and Cytotoxicity', CHEMMEDCHEM, 16, 2851-2863 (2021) [C1]

In silico approaches identified 1, N-(6-((4-bromo- benzyl)amino)hexyl)-3,5-bis(trifluoromethyl)benzene sulfonamide, as a potential inhibitor of the S100A2-p53 protein-p... [more]

In silico approaches identified 1, N-(6-((4-bromo- benzyl)amino)hexyl)-3,5-bis(trifluoromethyl)benzene sulfonamide, as a potential inhibitor of the S100A2-p53 protein-protein interaction, a validated pancreatic cancer drug target. Subsequent cytotoxicity screening revealed it to be a 2.97 µM cell growth inhibitor of the MiaPaCa-2 pancreatic cell line. This is in keeping with our hypothesis that inhibiting this interaction would have an anti-pancreatic cancer effect with S100A2, the validated PC drug target. A combination of focused library synthesis (three libraries, 24 compounds total) and cytotoxicity screening identified a propyl alkyl diamine spacer as optimal; the nature of the terminal phenyl substituent had limited impact on observed cytotoxicity, whereas N-methylation was detrimental to activity. In total 15 human cancer cell lines were examined, with most analogues showing broad-spectrum activity. Near uniform activity was observed against a panel of six pancreatic cancer cell lines: MiaPaCa-2, BxPC-3, AsPC-1, Capan-2, HPAC and PANC-1. In all cases there was good to excellent correlation between the predicted docking pose in the S100A2-p53 binding groove and the observed cytotoxicity, especially in the pancreatic cancer cell line with high endogenous S100A2 expression. This supports S100A2 as a pancreatic cancer drug target.

DOI 10.1002/cmdc.202000949
Citations Scopus - 4Web of Science - 4
Co-authors C Scarlett, Jennifer R Baker, Adam Mccluskey, Cecilia Russell
2021 Sun J, Baker JR, Russell CC, Cossar PJ, Ngoc Thuy Pham H, Sakoff JA, Scarlett CJ, McCluskey A, 'Cytotoxic 1,2,3-Triazoles as Potential Leads Targeting the S100A2-p53 Complex: Synthesis and Cytotoxicity', CHEMMEDCHEM, 16, 2864-2881 (2021) [C1]

In silico screening predicted 1 (N-(4-((4-(3-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)propyl)piperazin-1-yl) sulfonyl)-phenyl)acetamide) as an inhibitor of the S100A2... [more]

In silico screening predicted 1 (N-(4-((4-(3-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)propyl)piperazin-1-yl) sulfonyl)-phenyl)acetamide) as an inhibitor of the S100A2-p53 protein-protein interaction. S100A2 is a validated pancreatic cancer drug target. In the MiaPaCa-2 pancreatic cell line, 1 was a ~50 µM growth inhibitor. Synthesis of five focused compound libraries and cytotoxicity screening revealed increased activity from the presence of electron withdrawing moieties on the sulfonamide aromatic ring, with the 3,5-bis-CF3 Library 3 analogues the most active, with GI50 values of 0.91 (3-ClPh; 13 i; BxPC-3, Pancreas) to 9.0 µM (4-CH3; 13 d; PANC-1, Pancreas). Activity was retained against an expanded pancreatic cancer cell line panel (MiaPaCa-2, BxPC-3, AsPC-1, Capan-2, PANC-1 and HPAC) and the normal cell line MCF10A (breast). Bulky 4-disposed substituents on the terminal phenyl ring enhanced broad spectrum activity with growth inhibition values spanning 1.1 to 3.1 µM (4-C(CH3)3; 13 e; BxPC-3 and AsPC-1 (pancreas), respectively). Central alkyl spacer contraction from propyl to ethyl proved detrimental to activity with Library 4 and 5.5- to 10-fold less cytotoxic than the propyl linked Library 2 and Library 3. The data herein was consistent with the predicted binding poses of the compounds evaluated. The highest levels of cytotoxicity were observed with those analogues best capable of adopting a near identical pose to the p53-peptide in the S100A2-p53 binding groove.

DOI 10.1002/cmdc.202000950
Citations Scopus - 6Web of Science - 7
Co-authors C Scarlett, Jennifer R Baker, Adam Mccluskey, Cecilia Russell
2021 Holland I, Bakri YM, Sakoff J, Pinet DZ, Motti C, van Altena I, 'Bioactive alpha,beta-conjugated 3-keto-steroids from the Australian brown alga Cystophora xiphocarpa', PHYTOCHEMISTRY, 188 (2021) [C1]

As part of our ongoing study of the specialised metabolites present in brown algae belonging to the Cystophora genus, eight new steroids including three pairs of diaste... [more]

As part of our ongoing study of the specialised metabolites present in brown algae belonging to the Cystophora genus, eight new steroids including three pairs of diastereoisomers were isolated from Cystophora xiphocarpa (Harvey) (Sargassacea, Fucales). The metabolites identified by standard spectrometric methods are (16S,22S)-16,22-dihydroxyergosta-4,24(28)-dien-3-one and (16S,22R)-16,22-dihydroxyergosta-4,24(28)-dien-3-one, (16S,22S,24R)-16,22,24-trihydroxyporifera-4,28-dien-3-one and (16S,22S,24S)-16,22,24-trihydroxystigma-4,28-dien-3-one along with (16S,22S,24E)-16,22-dihydroxystigma-4,24(28)-dien-3-one and (16S,20S)-16,20-dihydroxyergosta-4,24(28)-dien-3-one. (16S,22S,24E)-16,22-Dihydroxystigma-4,24(28)-dien-3-one possessed the most potent cytotoxicity of the steroids in this series with cell growth inhibitions of GI50 8.7 ± 0.7 µM against colon cancer HT29, GI50 5.6 ± 0.8 µM against the breast cancer line MCF-7 and GI50 4.5 ± 0.2 µM against the ovarian cancer cell line A2780. (16S,22R)-16,22-dihydroxyergosta-4,24(28)-dien-3-one was found to be active against the ovarian cancer cell line A2780 with a GI50 of 6.2 ± 0.1 µM.

DOI 10.1016/j.phytochem.2021.112798
Citations Scopus - 3Web of Science - 2
Co-authors Ian Vanaltena
2020 Gilbert J, De Iuliis GN, McCluskey A, Sakoff JA, 'A novel naphthalimide that selectively targets breast cancer via the arylhydrocarbon receptor pathway', Scientific Reports, 10 (2020) [C1]
DOI 10.1038/s41598-020-70597-8
Citations Scopus - 1Web of Science - 1
Co-authors Adam Mccluskey, Geoffry DeiuliIs
2020 Baker JR, Russell CC, Gilbert J, Sakoff JA, McCluskey A, 'Amino Alcohol Acrylonitriles as Activators of the Aryl Hydrocarbon Receptor Pathway: An Unexpected MTT Phenotypic Screening Outcome', ChemMedChem, 15, 490-505 (2020) [C1]
DOI 10.1002/cmdc.201900643
Citations Scopus - 1Web of Science - 1
Co-authors Adam Mccluskey, Jennifer R Baker, Cecilia Russell
2020 Md Yusof EN, Latif MAM, Tahir MIM, Sakoff JA, Veerakumarasivam A, Page AJ, Tiekink ERT, Ravoof TBSA, 'Homoleptic tin(IV) compounds containing tridentate ONS dithiocarbazate Schiff bases: Synthesis, X-ray crystallography, DFT and cytotoxicity studies', Journal of Molecular Structure, 1205 (2020) [C1]
DOI 10.1016/j.molstruc.2019.127635
Citations Scopus - 2Web of Science - 1
Co-authors Alister Page
2020 Baker JR, Sakoff JA, McCluskey A, 'Cover Image, Volume 40, Issue 3', Medicinal Research Reviews, 40 (2020)
DOI 10.1002/med.21610
Co-authors Jennifer R Baker, Adam Mccluskey
2020 Yusof ENM, Page AJ, Sakoff JA, Simone MI, Veerakumarasivam A, Tiekink ERT, Ravoof TBSA, 'Tin(IV) compounds of tridentate thiosemicarbazone Schiff bases: Synthesis, characterization, in-silico analysis and in vitro cytotoxicity', Polyhedron, 189 (2020) [C1]
DOI 10.1016/j.poly.2020.114729
Citations Scopus - 2Web of Science - 1
Co-authors Alister Page
2020 Yusof ENM, Ishak NNM, Latif MAM, Tahir MIM, Sakoff JA, Page AJ, Tiekink ERT, Ravoof TBSA, 'Selective cytotoxicity of organotin(IV) compounds with 2,3-dihydroxybenzyldithiocarbazate Schiff bases', Research on Chemical Intermediates, 46, 2351-2379 (2020) [C1]
DOI 10.1007/s11164-020-04095-x
Citations Scopus - 6Web of Science - 4
Co-authors Alister Page
2020 Baker JR, Sakoff JA, McCluskey A, 'The aryl hydrocarbon receptor (AhR) as a breast cancer drug target', Medicinal Research Reviews, 40, 972-1001 (2020) [C1]
DOI 10.1002/med.21645
Citations Scopus - 5Web of Science - 4
Co-authors Jennifer R Baker, Adam Mccluskey
2020 Scorgie FE, Garg MB, Gilbert J, Sakoff JA, Lincz LF, 'A simplified method to calculate telomere length from Southern blot images of terminal restriction fragment lengths', BioTechniques, 68, 28-34 (2020) [C1]
DOI 10.2144/btn-2019-0082
Citations Scopus - 1Web of Science - 1
Co-authors Lisa Lincz
2020 Bjelosevic A, Sakoff J, Gilbert J, Zhang Y, Gordon C, Aldrich-Wright JR, 'Synthesis, Characterisation, and Biological Activity of the Ruthenium Complexes of the N-4-Tetradentate (N-4-T-L), 1,6-Di(2 '-pyridyl)-2,5-dimethyl-2,5-diazahexane (picenMe(2))', AUSTRALIAN JOURNAL OF CHEMISTRY, 73, 956-968 (2020) [C1]

A series of complexes of the type rac-[Ru(N4-TL)(PL)]2+ (where N4-TL=1, 6-di(2'-pyridyl)-2, 5-dimethyl-2, 5-diazahexane (picenMe2, N4-TL-2) and PL=1, 10-phenanthro... [more]

A series of complexes of the type rac-[Ru(N4-TL)(PL)]2+ (where N4-TL=1, 6-di(2'-pyridyl)-2, 5-dimethyl-2, 5-diazahexane (picenMe2, N4-TL-2) and PL=1, 10-phenanthroline (phen, Ru-2), dipyrido[3, 2-d:2', 3'-f]quinoxaline (dpq, Ru-3), 7, 8-dimethyl-dipyrido[3, 2-a:2', 3'-c]phenazine (dppzMe2, Ru-4), 2-phenyl-1H-imidazo[4, 5-f][1, 10]phenanthroline (phenpyrBz, Ru-5), 2-(p-tolyl)-1H-imidazo[4, 5-f][1, 10]phenanthroline (phenpyrBzMe, Ru-6), and 2-(4-nitrophenyl)- 1H-imidazo[4, 5-f][1, 10]phenanthroline (phenpyrBzNO2, Ru-7), were synthesised. All structures were confirmed using NMR, electrospray ionisation mass spectrometry (ESI-MS), high-performance liquid chromatography (HPLC), and UV analysis and for four complexes X-ray crystallography. The in vitro cytotoxicity assays revealed that Ru-6 was 5, 10, and 40-fold more potent than oxaliplatin, cisplatin, and carboplatin, respectively.

DOI 10.1071/CH19528
Citations Scopus - 2Web of Science - 2
2019 Al Otaibi A, Deane FM, Russell CC, Hizartzidis L, McCluskey SN, Sakoff JA, McCluskey A, 'A methanol and protic ionic liquid Ugi multicomponent reaction path to cytotoxic a-phenylacetamido amides', RSC Advances, 9, 7652-7663 (2019) [C1]
DOI 10.1039/c9ra00118b
Citations Scopus - 7Web of Science - 7
Co-authors Adam Mccluskey, Cecilia Russell
2019 Deo KM, Sakoff J, Gilbert J, Zhang Y, Wright JRA, 'Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum(iv) prodrugs as potent anticancer agents', DALTON TRANSACTIONS, 48, 17228-17240 (2019) [C1]
DOI 10.1039/c9dt04049h
Citations Scopus - 3Web of Science - 28
2019 Deo KM, Sakoff J, Gilbert J, Zhang Y, Wright JRA, 'Synthesis, characterisation and potent cytotoxicity of unconventional platinum(iv) complexes with modified lipophilicity', DALTON TRANSACTIONS, 48, 17217-17227 (2019) [C1]
DOI 10.1039/c9dt03339d
Citations Scopus - 2Web of Science - 21
2019 Nadia Md Yusof E, Latif MAM, Tahir MIM, Sakoff J, Simone M, Page AJ, Veerakumarasivam A, Tiekink ERT, Ravoof TBSA, 'o-Vanillin Derived Schiff Bases and Their Organotin(IV) Compounds: Synthesis, Structural Characterisation, In-Silico Studies and Cytotoxicity', International Journal of Molecular Sciences, 20 (2019) [C1]
Citations Scopus - 4Web of Science - 3
Co-authors Alister Page
2019 McGhie BS, Sakoff J, Gilbert J, Aldrich-Wright JR, 'Synthesis and characterisation of platinum(IV) polypyridyl complexes with halide axial ligands', INORGANICA CHIMICA ACTA, 495 (2019) [C1]

A series of complexes of the type [Pt(PL)(AL)(X)2]2+ (where PL = 1,10-phenanthroline, 5-methyl-1,10-phenanthroline or 5,6-dimethyl-1,10-phenanthroline; AL = 1S,2S-diami... [more]

A series of complexes of the type [Pt(PL)(AL)(X)2]2+ (where PL = 1,10-phenanthroline, 5-methyl-1,10-phenanthroline or 5,6-dimethyl-1,10-phenanthroline; AL = 1S,2S-diaminocyclohexane and, X = Cl, Br or I) with anticancer potency, were synthesised in a one pot reaction using N-halogensuccinimide (NXS) as both the source of the ligand and the oxidizing reagent. It was determined that 2.4 equivalents of NXS resulted in 100% oxidation of Pt(II) in a solution of equal parts H2O, ethanol and 1 M HCl. This method of oxidation was 24 times faster than the established peroxide method resulting in the acceleration of the complete synthesis of [Pt(PL)(AL)(X)2]2+. All structures were confirmed using NMR, ESI-MS, CD and UV, while the purity was confirmed by microanalysis. The in vitro cytotoxicity assays revealed that they were more active than analogous complexes with hydroxido axial ligands, and share comparable activity with the corresponding Pt(II) complex.

DOI 10.1016/j.ica.2019.118964
Citations Scopus - 1Web of Science - 9
2019 Hizartzidis L, Gilbert J, Gordon CP, Sakoff JA, McCluskey A, 'Synthesis and Cytotoxicity of Octahydroepoxyisoindole-7-carboxylic Acids and Norcantharidin-Amide Hybrids as Norcantharidin Analogues', CHEMMEDCHEM, 14, 1152-1161 (2019) [C1]
DOI 10.1002/cmdc.201900180
Citations Scopus - 1Web of Science - 10
Co-authors Adam Mccluskey
2019 Pham HNT, Sakoff JA, Vuong QV, Bowyer MC, Scarlett CJ, 'Phytochemical, antioxidant, anti-proliferative and antimicrobial properties of Catharanthus roseus root extract, saponin-enriched and aqueous fractions', Molecular Biology Reports, 46, 3265-3273 (2019) [C1]
DOI 10.1007/s11033-019-04786-8
Citations Scopus - 2Web of Science - 1
Co-authors Michael Bowyer, C Scarlett, Vanquan Vuong
2018 Baker JR, Gilbert J, Paula S, Zhu X, Sakoff JA, McCluskey A, 'Dichlorophenylacrylonitriles as AhR Ligands That Display Selective Breast Cancer Cytotoxicity in vitro', CHEMMEDCHEM, 13, 1447-1458 (2018) [C1]
DOI 10.1002/cmdc.201800256
Citations Scopus - 2Web of Science - 24
Co-authors Adam Mccluskey, Jennifer R Baker
2018 Pages BJ, Sakoff J, Gilbert J, Zhang Y, Kelly SM, Hoeschele JD, Aldrich-Wright JR, 'Combining the platinum(II) drug candidate kiteplatin with 1,10-phenanthroline analogues', DALTON TRANSACTIONS, 47, 2156-2163 (2018) [C1]

Platinum complexes of the type [Pt(PL)(AL)]2+ where PL is a derivative of 1,10-phenanthroline and AL is cis-1,4-diaminocyclohexane (1,4-dach), have been synthesised and... [more]

Platinum complexes of the type [Pt(PL)(AL)]2+ where PL is a derivative of 1,10-phenanthroline and AL is cis-1,4-diaminocyclohexane (1,4-dach), have been synthesised and characterised by ultraviolet spectroscopy, elemental microanalysis, nuclear magnetic resonance and X-ray crystallography. The calf-thymus DNA binding affinity of these complexes was determined by isothermal titration calorimetry, revealing higher DNA affinity than their 1S,2S-diaminocyclohexane analogues. In vitro cytotoxicity was assessed in eleven human cell lines, revealing unexpectedly low activity for the 1,4-dach complexes.

DOI 10.1039/c7dt04108j
Citations Scopus - 7Web of Science - 5
2018 Hong NTP, Sakoff JA, Vuong QV, Bowyer MC, Scarlett CJ, 'Comparative cytotoxic activity between kaempferol and gallic acid against various cancer cell lines', DATA IN BRIEF, 21, 1033-1036 (2018) [C1]

This data article indicates the in vitro cytotoxicity of kaempferol and gallic acid across different cancer cell lines including A2780 (ovarian), H460 (lung), A431 (ski... [more]

This data article indicates the in vitro cytotoxicity of kaempferol and gallic acid across different cancer cell lines including A2780 (ovarian), H460 (lung), A431 (skin), MIA PaCa-2 (pancreas), Du145 (prostate), HT29 (colon), MCF-7 (breast), BE2-C (neuroblastoma), SJ-G2, U87 and SMA (glioblastoma). The dataset showed that the inhibitory activity of kaempferol was comparatively stronger than gallic acid. Thereby, kaempferol is offered as a potent anticancer agent for further investigation and beneficial as a dietary supplement. The data within this article relates to the research article entitled "Screening phytochemical content, antioxidant, antimicrobial and cytotoxic activities of Catharanthus roseus (L.) G. Don stem extract and its fractions" (Pham et al., 2018).

DOI 10.1016/j.dib.2018.10.121
Citations Scopus - 3Web of Science - 17
Co-authors Michael Bowyer, Vanquan Vuong, C Scarlett
2018 Pham HNT, Sakoff JA, Vuong QV, Bowyer MC, Scarlett CJ, 'Screening phytochemical content, antioxidant, antimicrobial and cytotoxic activities of Catharanthus roseus (L.) G. Don stem extract and its fractions', Biocatalysis and Agricultural Biotechnology, 16, 405-411 (2018) [C1]
DOI 10.1016/j.bcab.2018.09.005
Citations Scopus - 4Web of Science - 2
Co-authors Michael Bowyer, Vanquan Vuong, C Scarlett
2018 Gilbert J, De Iuliis GN, Tarleton M, McCluskey A, Sakoff JA, '(Z)-2-(3,4-dichlorophenyl)-3-(1H-pyrrol-2-yl)acrylonitrile exhibits selective antitumor activity in breast cancer cell lines via the aryl hydrocarbon receptor pathway', Molecular Pharmacology, 93, 168-177 (2018) [C1]
DOI 10.1124/mol.117.109827
Citations Scopus - 2Web of Science - 2
Co-authors Geoffry DeiuliIs, Adam Mccluskey
2018 Ghods A, Gilbert J, Baker JR, Russell CC, Sakoff JA, McCluskey A, 'A focused library synthesis and cytotoxicity of quinones derived from the natural product bolinaquinone', ROYAL SOCIETY OPEN SCIENCE, 5 (2018) [C1]

Bolinaquinone is a natural product that is a structurally complex, cytotoxic sesquiterpene quinone. A scaffold simplification and focused library approach using a micro... [more]

Bolinaquinone is a natural product that is a structurally complex, cytotoxic sesquiterpene quinone. A scaffold simplification and focused library approach using a microwave-assisted Suzuki coupling gave 32 bolinaquinone analogues with good-to-excellent cytotoxicity profiles. Mono-arylbenzoquinones, Library A, were preferentially toxic towards BE2-C (neuroblastoma) cells with growth inhibition (GI50) values of 4¿12 µM; only the 3,4-dimethoxyphenyl 23 and 3-biphenyl 28 variants were broad-spectrum active¿HT29 (colon carcinoma), U87 and SJ-G2 (glioblastoma), MCF-7 (breast carcinoma), A2780 (ovarian carcinoma), H460 (lung carcinoma), A431 (skin carcinoma), Du145 (prostate carcinoma), BE2-C (neuroblastoma), MIA (pancreatic carcinoma) and SMA (spontaneous murine astrocytoma). Library B with a second aryl moiety exhibited broad-spectrum cytotoxicity with MCF-7 cells' GI50 values of 5.6 ± 0.7 and 5.1 ± 0.5 µM for 2,5-dimethoxy-3-(naphthalene-1-yl)-6-(naphthalene-3-yl) 33 and 2,5-dimethoxy-3-(biaryl-2-yl)-6-(naphthalene-3-yl) 36, respectively. Similar potencies were also noted with 2,5-dimethoxy-3,6-diphenyl 30 against A2780 (GI50 = 5.9 ± 0.0 µM) and with 2,5-dimethoxy-3-(biaryl-3-yl)-6-(naphthalene-3-yl) 37 against HT29 (GI50 = 5.4 ± 0.4 µM), while the 3,4-dimethoxy mono-aryl analogue 23 exhibited good levels of activity against A2780 (GI50 = 3.8 ± 0.75 µM), the neuroblastoma cell line BE2-C (GI50 = 3 ± 0.35 µM) and SMA (GI50 = 3.9 ± 0.54 µM). Introduction of the amino-substituted Library C gave 2-(naphthalen-1-yl)-5-(naphthalen-3-yl)-3,6-bis(propylamino) 43, with excellent activity against HT29 (0.08 ± 0.0 µM), MCF-7 (0.17 ± 0.1 µM), A2780 (0.14 ± 0.1 µM), A431 (0.11 ± 0.0 µM), Du145 (0.16 ± 0.1 µM), BE2-C (0.08 ± 0.0 µM) and MIA (0.1 ± 0.0 µM).

DOI 10.1098/rsos.171189
Citations Scopus - 8Web of Science - 7
Co-authors Adam Mccluskey, Cecilia Russell, Jennifer R Baker
2018 Hong NTP, Sakoff JA, Bond DR, Quan VV, Bowyer MC, Scarlett CJ, 'In vitro antibacterial and anticancer properties of Helicteres hirsuta Lour. leaf and stem extracts and their fractions', MOLECULAR BIOLOGY REPORTS, 45, 2125-2133 (2018) [C1]
DOI 10.1007/s11033-018-4370-x
Citations Scopus - 1Web of Science - 16
Co-authors C Scarlett, Vanquan Vuong, Michael Bowyer, Danielle Bond
2017 Van TN, Sakoff JA, Scarlett CJ, 'Physicochemical, Antioxidant, and Cytotoxic Properties of Xao Tam Phan (Paramignya trimera) Root Extract and Its Fractions', CHEMISTRY & BIODIVERSITY, 14 (2017) [C1]
DOI 10.1002/cbdv.201600396
Citations Scopus - 2Web of Science - 17
Co-authors C Scarlett
2017 Nguyen VT, Sakoff JA, Scarlett CJ, 'Physicochemical Properties, Antioxidant and Cytotoxic Activities of Crude Extracts and Fractions from Phyllanthus amarus.', Medicines, 4 (2017) [C1]
DOI 10.3390/medicines4020042
Co-authors C Scarlett
2017 Bhuyan DJ, Sakoff J, Bond DR, Predebon M, Vuong QV, Chalmers AC, van Altena IA, Bowyer MC, Scarlett CJ, 'In vitro anticancer properties of selected Eucalyptus species', IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 53, 604-615 (2017) [C1]
DOI 10.1007/s11626-017-0149-y
Citations Scopus - 2Web of Science - 18
Co-authors Michael Bowyer, C Scarlett, Ian Vanaltena, Danielle Bond, Anita Chalmers, Vanquan Vuong
2017 Cossar PJ, Abdel-Hamid MK, Ma C, Sakoff JA, Trinh TN, Gordon CP, Lewis PJ, McCluskey A, 'Small-Molecule Inhibitors of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity', ACS OMEGA, 2, 3839-3857 (2017) [C1]
DOI 10.1021/acsomega.7b00273
Citations Scopus - 1Web of Science - 10
Co-authors Peter Lewis, Trieu N Trinh, Adam Mccluskey
2017 Spare LK, Falsetta P, Gilbert J, Harman DG, Baker MA, Li F, McCluskey A, Clegg JK, Sakoff JA, Aldrich-Wright JR, Gordon CP, 'Cytotoxicity of a Series of Norcantharidin-Inspired Tetrahydroepoxyisoindole Carboxamides', CHEMMEDCHEM, 12, 130-145 (2017) [C1]
DOI 10.1002/cmdc.201600573
Citations Scopus - 7Web of Science - 6
Co-authors Mark Baker, Adam Mccluskey
2017 Odell LR, Abdel-Hamid MK, Hill TA, Ngoc C, Young KA, Deane FM, Sakoff JA, Andersson S, Daniel JA, Robinson PJ, McCluskey A, 'Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain', JOURNAL OF MEDICINAL CHEMISTRY, 60, 349-361 (2017) [C1]
DOI 10.1021/acs.jmedchem.6b01422
Citations Web of Science - 20
Co-authors Adam Mccluskey
2017 Van TN, Sakoff JA, Scarlett CJ, 'Physicochemical Properties, Antioxidant and Anti-proliferative Capacities of Dried Leaf and Its Extract from Xao tam phan (Paramignya trimera)', CHEMISTRY & BIODIVERSITY, 14 (2017) [C1]
DOI 10.1002/cbdv.201600498
Citations Scopus - 2Web of Science - 18
Co-authors C Scarlett
2016 Zaleta-Pinet D, McCluskey A, Hall S, Brophy J, Ashhurst-Smith C, Sakoff J, van Altena I, 'The Use of the Toxic Plant Myoporum montanum in a Traditional Australian Aboriginal Medicine', AUSTRALIAN JOURNAL OF CHEMISTRY, 69, 161-168 (2016) [C1]

Plants from the family Myoporaceae, which includes the genus Myoporum, are extremely prized by the Australian Aboriginal people for their medicinal properties. Leaves f... [more]

Plants from the family Myoporaceae, which includes the genus Myoporum, are extremely prized by the Australian Aboriginal people for their medicinal properties. Leaves from a plant, which was subsequently identified as Myoporum montanum, were provided for chemical investigation by representatives of an Aboriginal community from the Northern Tablelands district of northern New South Wales, Australia. Acetone extraction of the leaves provided a complex mixture of compounds including sesquiterpene hydrocarbons and more polar furanosesquiterpenes, which were identified by gas-liquid chromatography and retention indices (sesquiterpene hydrocarbons) and spectrometric techniques (furanosesquiterpenes). The major compounds found in a water extract were studied for their antibacterial activity using a disc diffusion assay and for their cell growth inhibition activity. The acetone extract contained sesquiterpene hydrocarbons (~30% of the total extract) in which the major compounds were germacrene-D and bicyclogermacrene. In addition, the extract contained five known toxic furanosesquiterpenes: myoporum ketol, (-)-10,11-dehydroisomyodesmone, (+)-10,11-dehydromyodesmone, 10,11-dehydromyoporum ketol, (-)-10,11-dehydromyoporone, and (±)-myoporone. An aqueous extract of the leaves, emulating the medicinal tea used by the Australian Aboriginal community, was found not to contain significant quantities of the sesquiterpene hydrocarbons and the most toxic furanosesquiterpenes. (±)-Myoporone and (-)-10,11-dehydromyoporone remained in the extract as well as a new furanosesquiterpene, 11-hydroxymyoporone. These three compounds were found to have significant antibacterial activity against Staphylococcus epidermidis, Enterococcus faecalis, and Moraxella catarrhalis but low cytotoxicity against a range of cancer cell lines and normal breast cells at 25µM.

DOI 10.1071/CH15586
Citations Scopus - 8Web of Science - 8
Co-authors Adam Mccluskey, Ian Vanaltena, Sharron Hall
2016 Pages BJ, Sakoff J, Gilbert J, Rodger A, Chmel NP, Jones NC, Kelly SM, Ang DL, Aldrich-Wright JR, 'Multifaceted Studies of the DNA Interactions and In Vitro Cytotoxicity of Anticancer Polyaromatic Platinum(II) Complexes', CHEMISTRY-A EUROPEAN JOURNAL, 22, 8943-8954 (2016) [C1]

This study reports a detailed biophysical analysis of the DNA binding and cytotoxicity of six platinum complexes (PCs). They are of the type [Pt(PL)(SS-dach)]Cl2, where... [more]

This study reports a detailed biophysical analysis of the DNA binding and cytotoxicity of six platinum complexes (PCs). They are of the type [Pt(PL)(SS-dach)]Cl2, where PLis a polyaromatic ligand and SS-dach is 1S,2S-diaminocyclohexane. The DNA binding of these complexes was investigated using six techniques including ultraviolet and fluorescence spectroscopy, linear dichroism, synchrotron radiation circular dichroism, isothermal titration calorimetry and mass spectrometry. This portfolio of techniques has not been extensively used to study the interactions of such complexes previously; each assay provided unique insight. The in vitro cytotoxicity of these compounds was studied in ten cell lines and compared to the effects of their R,R enantiomers; activity was very high in Du145 and SJ-G2 cells, with some submicromolar IC50values. In terms of both DNA affinity and cytotoxicity, complexes of 5,6-dimethyl-1,10-phenanthroline and 2,2'-bipyridine exhibited the greatest and least activity, respectively, suggesting that there is some correlation between DNA binding and cytotoxicity.

DOI 10.1002/chem.201601221
Citations Scopus - 2Web of Science - 20
2016 Pages BJ, Sakoff J, Gilbert J, Zhang Y, Li F, Preston D, Crowley JD, Aldrich-Wright JR, 'Investigating the cytotoxicity of platinum(II) complexes incorporating. bidentate pyridy1-1,2,3-triazole "click" ligands', JOURNAL OF INORGANIC BIOCHEMISTRY, 165, 92-99 (2016)
DOI 10.1016/j.jinorgbio.2016.06.017
Citations Scopus - 2Web of Science - 21
2016 Trinh TN, McLaughlin EA, Abdel-Hamid MK, Gordon CP, Bernstein IR, Pye V, Cossar P, Sakoff JA, McCluskey A, 'Quinolone-1-(2H)-ones as hedgehog signalling pathway inhibitors', ORGANIC & BIOMOLECULAR CHEMISTRY, 14, 6304-6315 (2016) [C1]
DOI 10.1039/c6ob00606j
Citations Scopus - 9Web of Science - 9
Co-authors Eileen Mclaughlin, Trieu N Trinh, Adam Mccluskey
2016 Chuen TLK, Vuong QV, Hirun S, Bowyer MB, Predebon MJ, Goldsmith CD, Sakoff JA, Scarlett CJ, 'Antioxidant and anti-proliferative properties of Davidson’s plum (Davidsonia pruriens F. Muell) phenolic-enriched extracts as affected by different extraction solvents', Journal of Herbal Medicine, 6, 187-192 (2016) [C1]
DOI 10.1016/j.hermed.2016.08.005
Citations Scopus - 3Web of Science - 2
Co-authors Michael Bowyer, C Scarlett, Vanquan Vuong
2016 Lin AJS, Russell CC, Baker JR, Frailey SL, Sakoff JA, McCluskey A, 'A facile hybrid 'flow and batch' access to substituted 3,4-dihydro-2H-benzo[b][1,4] oxazinones', ORGANIC & BIOMOLECULAR CHEMISTRY, 14, 8732-8742 (2016) [C1]

We describe a simple flow chemistry approach to libraries of ethyl 3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylates (12a-l) and N-et... [more]

We describe a simple flow chemistry approach to libraries of ethyl 3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylates (12a-l) and N-ethyl-3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamides (13a-l) in 38-87% yields. This scaffold is poorly described in the chemical literature. Screening against a panel of 11 cancer and one normal cell line showed that the amide linked library 13a-l was devoid of toxicity. Whereas the ester linked analogues 12b, 12c, 12g, 12j and 12l were highly cytotoxic with growth inhibition (GI50) values from 0.34 to >50 µM across all cell lines, with the 2-OH-Ph substituted 12l analogue presenting with sub-micromolar potency against the A2780 (ovarian; 0.34 ± 0.04 µM), BEC-2 (glioblastoma; 0.35 ± 0.06 µM), MIA (pancreas; 0.91 ± 0.054 µM) and SMA (murine glioblastoma; 0.77 ± 0.029 µM) carcinoma cell lines. Interestingly, the U87 glioblastoma cell line showed inherent resistance to growth inhibition by all analogues (GI50 32 to >50 µM) while the A2780 cells were highly sensitive (GI50 3.8-0.34 µM), suggesting that the analogues developed herein may be valuable lead compounds for the development of ovarian carcinoma specific cytotoxic agents. The differences in amide versus ester cytotoxicity was consitent with esterase cleaveage to release the cytotoxic warhead.

DOI 10.1039/c6ob01153e
Citations Scopus - 4Web of Science - 4
Co-authors Jennifer R Baker, Adam Mccluskey, Cecilia Russell
2015 MacIas FJ, Deo KM, Pages BJ, Wormell P, Clegg JK, Zhang Y, Li F, Zheng G, Sakoff J, Gilbert J, Aldrich-Wright JR, 'Synthesis and Analysis of the Structure, Diffusion and Cytotoxicity of Heterocyclic Platinum(IV) Complexes', Chemistry - A European Journal, 21, 16990-17001 (2015) [C1]

We have developed six dihydroxidoplatinum(IV) compounds with cytotoxic potential. Each derived from active platinum(II) species, these complexes consist of a heterocycl... [more]

We have developed six dihydroxidoplatinum(IV) compounds with cytotoxic potential. Each derived from active platinum(II) species, these complexes consist of a heterocyclic ligand (HL) and ancillary ligand (AL) in the form [Pt(HL)(AL)(OH)2]2+, where HL is a methyl-functionalised variant of 1,10-phenanthroline and AL is the S,S or R,R isomer of 1,2-diaminocyclohexane. NMR characterisation and X-ray diffraction studies clearly confirmed the coordination geometry of the octahedral platinum(IV) complexes. The self-stacking of these complexes was determined using pulsed gradient stimulated echo nuclear magnetic resonance. The self-association behaviour of square planar platinum(II) complexes is largely dependent on concentration, whereas platinum(IV) complexes do not aggregate under the same conditions, possibly due to the presence of axial ligands. The cytotoxicity of the most active complex, exhibited in several cell lines, has been retained in the platinum(IV) form.

DOI 10.1002/chem.201502159
Citations Scopus - 3Web of Science - 2
2015 Pages BJ, Zhang Y, Li F, Sakoff J, Gilbert J, Aldrich-Wright JR, 'Cytotoxicity and Structural Analyses of 2,2'-Bipyridine-, 4,4'-Dimethyl-2,2'-bipyridine- and 2-(2'-Pyridyl)quinoxalineplatinum(II) Complexes', European Journal of Inorganic Chemistry, 2015, 4167-4175 (2015) [C1]

Platinum anticancer complexes incorporating 2,2'-bipyridine (bpy), 4,4'-dimethyl-2,2'-bipyridine (44Me2bpy) or 2-(2'-pyridyl)quinoxaline (2pq) as po... [more]

Platinum anticancer complexes incorporating 2,2'-bipyridine (bpy), 4,4'-dimethyl-2,2'-bipyridine (44Me2bpy) or 2-(2'-pyridyl)quinoxaline (2pq) as polyaromatic ligands and the S,S or R,R isomer of 1,2-diaminocyclohexane as ancillary ligands in the form [Pt(PL)(AL)]2+ have been synthesised and characterised. X-ray diffraction was used to elucidate the structure and stacking behaviour of the complexes, revealing interesting properties that may impact their biological activity. Pulsed gradient spin-echo NMR experiments elucidated the aggregation behaviour of these complexes in solution. The cytotoxicity of each complex was assessed against the L1210 murine leukaemia, HT29 human colon carcinoma and U87 human glioblastoma cell lines and compared to other complexes within this class. The complexes incorporating 44Me2bpy were found to be the most potent at inhibiting cell growth with IC50 values for the S,S isomer (0.13-0.5 µM) less than that for cisplatin (0.36-11 µM), oxaliplatin (0.9-1.8 µM) or carboplatin (>50 µM). Most complexes were found to be very effective against HT29 colon carcinoma cells.

DOI 10.1002/ejic.201500754
Citations Scopus - 2Web of Science - 2
2015 Vuong QV, Hirun S, Chuen TLK, Goldsmith CD, Munro B, Bowyer MC, Chalmers AC, Sakoff JA, Phillips PA, Scarlett CJ, 'Physicochemical, antioxidant and anti-cancer activity of a Eucalyptus robusta (Sm.) leaf aqueous extract', INDUSTRIAL CROPS AND PRODUCTS, 64, 167-174 (2015) [C1]
DOI 10.1016/j.indcrop.2014.10.061
Citations Scopus - 3Web of Science - 1
Co-authors Vanquan Vuong, Anita Chalmers, C Scarlett, Michael Bowyer
2015 Rixson JE, Abraham JR, Egoshi Y, Skelton BW, Young K, Gilbert J, Sakoff JA, Gericke KM, McCluskey A, Stewart SG, 'The synthesis and biological activity of novel anthracenone-pyranones and anthracenone-furans', BIOORGANIC & MEDICINAL CHEMISTRY, 23, 3552-3565 (2015) [C1]

Abstract An efficient and divergent methodology for the synthesis of new anthracenone-pyranones and anthracenone-furans is described. Key reactions discussed in these s... [more]

Abstract An efficient and divergent methodology for the synthesis of new anthracenone-pyranones and anthracenone-furans is described. Key reactions discussed in these syntheses include an aldehyde promoted annulation with a ß-keto-sulfoxide, a domino alkyne insertion/carbonylation/Nu-acylation and a DMEDA promoted Castro-Stephens reaction. We also report the in vitro growth inhibition of these compounds in a range of human cancer cells. The natural product BE-26554A displayed good cell growth activity on BE2-C neuroblastoma and SMA glioblastoma cell lines at 0.17 and 0.16 µM (GI50), respectively. Of note, were a CF3 functionalised anthracenone 4-pyranone (chromone) derivative 22, and an anthracenone-furan derivative 54 which displayed 0.20 µM and 0.38 µM growth inhibition, respectively, in the BE2-C neuroblastoma cell line.

DOI 10.1016/j.bmc.2015.04.032
Citations Web of Science - 8
Co-authors Adam Mccluskey
2015 Macias FJ, Deo KM, Pages BJ, Wormell P, Clegg JK, Zhang Y, Li F, Zheng G, Sakoff J, Gilbert J, Aldrich-Wright JR, 'Synthesis and Analysis of the Structure, Diffusion and Cytotoxicity of Heterocyclic Platinum(IV) Complexes.', Chemistry (Weinheim an der Bergstrasse, Germany), 21, 16990-17001 (2015)
DOI 10.1002/chem.201502159
2014 Al Otaibi A, Gordon CP, Gilbert J, Sakoff JA, McCluskey A, 'The influence of ionic liquids on the Knoevenagel condensation of 1H-pyrrole-2-carbaldehyde with phenyl acetonitriles - cytotoxic 3-substituted-(1H-pyrrol-2-yl)acrylonitriles', RSC ADVANCES, 4, 19806-19813 (2014) [C1]

The Knoevenagel condensation of a series of substituted phenyl acetonitriles with 1H-pyrrole-2-carbaldehyde was examined in seven 1-butyl-3-methylimidazolium based ioni... [more]

The Knoevenagel condensation of a series of substituted phenyl acetonitriles with 1H-pyrrole-2-carbaldehyde was examined in seven 1-butyl-3-methylimidazolium based ionic liquids and three protic ionic liquids. Of these [BMIM][Br] and [BMIM][OH], with catalytic piperidine, proved most efficient affording 3-substituted-(1H-pyrrol-2-yl)acrylonitriles 3-17 in good to excellent yields (98%) whilst utilisation of the protic ionic liquid propyl ammonium nitrate resulted in reduced yields (0-66%). Screening of the 3-substituted-(1H-pyrrol-2-yl)acrylonitriles analogues 3-17 against a panel of 11 cancer cell lines and one normal cell line allowed the identification of a series of compounds with broad spectrum cytotoxicity, but more interestingly a significant degree of MCF-7 breast cancer cell line specificity was evident with 6 (7 to >25 fold) and 13 (5.7 to >80 fold). Other analogues show high level of efficacy against specific cell lines with 10 showing excellent activity against MCF-7 (GI50 = 1.7 µM) and A431 (GI50 = 2.8 µM) cell lines. The most promising of the compounds identified herein were the 4-CF3 substituted 10 and the 3,4-dichloro substituted 13 with excellent activities against MCF-7 and A431 cell lines. The 3,4-dichloro-13 was a 0.56 µM potent inhibitor of MCF-7 cell growth. © 2014 the Partner Organisations.

DOI 10.1039/c3ra47418f
Citations Scopus - 7Web of Science - 1
Co-authors Adam Mccluskey
2014 Zaleta-Pinet DA, Holland IP, Muñoz-Ochoa M, Murillo-Alvarez JI, Sakoff JA, van Altena IA, McCluskey A, 'Cytotoxic compounds from Laurencia pacifica', Organic and Medicinal Chemistry Letters, 4 (2014)
DOI 10.1186/s13588-014-0008-8
Citations Scopus - 20
Co-authors Adam Mccluskey, Ian Vanaltena
2014 Vuong QV, Sadeqzadeh E, Hirun S, Goldsmith CD, Zammitt N, Bowyer MB, Sakoff JA, Thorne RF, Weidenhofer J, Scarlett CJ, 'Phenolic Compounds, Antioxidant and Anti-Cancer Properties of the Australian Maroon Bush Scaevola spinescens (Goodeniaceae)', Journal of Bioanalysis & Biomedicine, S12 (2014) [C1]
DOI 10.4172/1948-593X.S12-002
Co-authors C Scarlett, Vanquan Vuong, Judith Weidenhofer, Michael Bowyer
2014 Gordon CP, Hizartzidis L, Tarleton M, Sakoff JA, Gilbert J, Campbell BE, Gasser RB, McCluskey A, 'Discovery of acrylonitrile-based small molecules active against Haemonchus contortus', MEDCHEMCOMM, 5, 159-164 (2014) [C1]
DOI 10.1039/c3md00255a
Citations Scopus - 1Web of Science - 3
Co-authors Adam Mccluskey
2014 Dyson L, Wright AD, Young KA, Sakoff JA, McCluskey A, 'Synthesis and anticancer activity of focused compound libraries from the natural product lead, oroidin', BIOORGANIC & MEDICINAL CHEMISTRY, 22, 1690-1699 (2014) [C1]

Oroidin (1), (E)-N-(3-(2-amino-1H-imidazol-4-yl)allyl)-4,5-dibromo-1H- pyrrole-2-carboxamide, is a pyrrole alkaloid isolated from the marine sponge Agelas oroides. Rout... [more]

Oroidin (1), (E)-N-(3-(2-amino-1H-imidazol-4-yl)allyl)-4,5-dibromo-1H- pyrrole-2-carboxamide, is a pyrrole alkaloid isolated from the marine sponge Agelas oroides. Routine screening in a panel of twelve cancer cell lines revealed 1 to be poorly cytotoxic with the 50% growth inhibition concentration (GI) of 42 µM in MCF-7 (breast) cells and 24 µM in A2780 (ovarian) cells and >50 µM in all other cell lines tested. The development of eight focused libraries comprising thirty compounds total identified N-(biphenyl-4-ylmethyl)-1H-pyrrole-2-carboxamide (4l), N-benzyl-4,5-dibromo-1H- pyrrole-2-carboxamide (5a) and N-(biphenyl-4-ylmethyl)-4,5-dibromo-1H-pyrrole-2- carboxamide (5l) as potent inhibitors of cell growth in our panel of cell lines. Of these compounds GI values of <5 µM were observed with 4l against HT29 (colon) and SW480 (colon); 5a against HT29; and 5l against HT29, SW480, MCF-7, A431 (skin), Du145 (prostate), BE2-C (neuroblastoma) and MIA (pancreas) cell lines. As a cancer class, colon cancer appears to be more sensitive to the oroidin series of compounds, with analogue 5l being the most active. © 2014 Elsevier Ltd. All rights reserved.

DOI 10.1016/j.bmc.2014.01.021
Citations Web of Science - 4
Co-authors Adam Mccluskey
2013 Tarleton M, Dyson L, Gilbert J, Sakoff JA, McCluskey A, 'Focused library development of 2-phenylacrylamides as broad spectrum cytotoxic agents', BIOORGANIC & MEDICINAL CHEMISTRY, 21, 333-347 (2013) [C1]
DOI 10.1016/j.bmc.2012.10.003
Citations Scopus - 2Web of Science - 5
Co-authors Adam Mccluskey
2013 McCluskey A, Daniel JA, Hadzic G, Ngoc C, Clayton EL, Mariana A, et al., 'Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis', TRAFFIC, 14 1272-1289 (2013)
DOI 10.1111/tra.12119
Citations Web of Science - 219
Co-authors Adam Mccluskey
2013 McCluskey A, Daniel JA, Hadzic G, Ngoc C, Clayton EL, Mariana A, Whiting A, Gorgani NN, Lloyd J, Quan A, Moshkanbaryans L, Krishnan S, Perera S, Chircop M, von Kleist L, McGeachie AB, Howes MT, Parton RG, Campbell M, Sakoff JA, Wang X, Sun J-Y, Robertson MJ, Deane FM, Nguyen TH, Meunier FA, Cousin MA, Robinson PJ, 'Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis', CONTACT DERMATITIS, 69, 1272-1289 (2013) [C1]
DOI 10.1111/tra.12119
Citations Web of Science - 3
Co-authors Adam Mccluskey
2013 Deane FM, O'Sullivan EC, Maguire AR, Gilbert J, Sakoff JA, McCluskey A, McCarthy FO, 'Synthesis and evaluation of novel ellipticines as potential anti-cancer agents', Organic & Biomolecular Chemistry, 11, 1334-1344 (2013) [C1]
DOI 10.1039/c2ob27186a
Citations Scopus - 5Web of Science - 1
Co-authors Adam Mccluskey
2013 McGeachie AB, Odell LR, Quan A, Daniel JA, Chau N, Hill TA, Gorgani NN, Keating DJ, Cousin MA, Van Dam EM, Mariana A, Whiting A, Perera S, Novelle A, Young KA, Deane FM, Gilbert J, Sakoff JA, Chircop M, McCluskey A, Robinson PJ, 'Pyrimidyn compounds: Dual-action small molecule pyrimidine-based dynamin inhibitors', ACS Chemical Biology, 8, 1507-1518 (2013) [C1]
DOI 10.1021/cb400137p
Citations Scopus - 2Web of Science - 7
Co-authors Adam Mccluskey
2012 Tarleton MJ, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis and anticancer activity of a series of norcantharidin analogues', European Journal of Medicinal Chemistry, 54, 573-581 (2012) [C1]
Citations Scopus - 4Web of Science - 1
Co-authors Adam Mccluskey
2012 Tarleton MJ, Gilbert J, Sakoff JA, McCluskey A, 'Cytotoxic 2-phenyacrylnitriles, the importance of the cyanide moiety and discovery of potent broad spectrum cytotoxic agents', European Journal of Medicinal Chemistry, 57, 65-73 (2012) [C1]
DOI 10.1016/j.ejmech.2012.09.019
Citations Scopus - 3Web of Science - 8
Co-authors Adam Mccluskey
2012 Garg MB, Lincz L, Adler K, Scorgie FE, Ackland S, Sakoff JA, 'Predicting 5-Fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length - A multivariate analysis', British Journal of Cancer, 107, 1525-1533 (2012) [C1]
Citations Scopus - 6Web of Science - 6
Co-authors Lisa Lincz, Stephen Ackland
2011 Chircop M, Perera S, Mariana A, Lau H, Ma MPC, Gilbert J, Jones NC, Gordon CP, Young KA, Morokoff A, Sakoff J, O'Brien TJ, McCluskey A, Robinson PJ, 'Inhibition of dynamin by dynole 34-2 induces cell death following cytokinesis failure in cancer cells', Molecular Cancer Therapeutics, 10, 1553-1562 (2011) [C1]
DOI 10.1158/1535-7163.mct-11-0067
Citations Scopus - 5Web of Science - 2
Co-authors Adam Mccluskey
2011 Garg MB, Sakoff JA, Ackland S, 'A simple HPLC method for plasma level monitoring of mitotane and its two main metabolites in adrenocortical cancer patients', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 879, 2201-2205 (2011) [C1]
Citations Scopus - 1Web of Science - 6
Co-authors Manohar Garg, Stephen Ackland
2011 Tarleton MJ, Gilbert J, Robertson MJ, McCluskey A, Sakoff JA, 'Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound', MedChemComm, 2, 31-37 (2011) [C1]
DOI 10.1039/c0md00147c
Citations Scopus - 5Web of Science - 1
Co-authors Adam Mccluskey
2011 Von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, Macgregor KA, Tomlin N, Pechstein A, Chau N, Chircop M, Sakoff JA, Von Kries JP, Saenger W, Krausslich H-G, Shupliakov O, Robinson PJ, McCluskey A, Haucke V, 'Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition', Cell, 146, 471-484 (2011) [C1]
DOI 10.1016/j.cell.2011.06.025
Citations Scopus - 4Web of Science - 1
Co-authors Adam Mccluskey
2011 Campbell BE, Tarleton MJ, Gordon CP, Sakoff JA, Gilbert J, McCluskey A, Gasser RB, 'Norcantharidin analogues with nematocidal activity in Haemonchus contortus', Bioorganic and Medicinal Chemistry Letters, 21, 3277-3281 (2011) [C1]
DOI 10.1016/j.bmcl.2011.04.031
Citations Scopus - 3Web of Science - 2
Co-authors Adam Mccluskey
2011 Robertson MJ, Gordon CP, Gilbert J, McCluskey A, Sakoff JA, 'Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity', Bioorganic & Medicinal Chemistry, 19, 5734-5741 (2011) [C1]
DOI 10.1016/j.bmc.2011.01.031
Citations Scopus - 2Web of Science - 1
Co-authors Adam Mccluskey
2011 von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, MacGregor KA, Tomilin N, Pechstein A, Chau N, Chircop M, Sakoff J, von Kries JP, Saenger W, Kraeusslich H-G, Shupliakov O, Robinson PJ, McCluskey A, Haucke V, 'Role of the Clathrin Terminal Domain in Regulating Coated Pit Dynamics Revealed by Small Molecule Inhibition (vol 146, pg 471, 2011)', CELL, 146, 841-841 (2011)
DOI 10.1016/j.cell.2011.08.014
Citations Scopus - 6Web of Science - 2
Co-authors Adam Mccluskey
2010 Joshi S, Perera S, Gilbert J, Smith CM, Mariana A, Gordon CP, Sakoff JA, McCluskey A, Robinson PJ, Braithwaite AW, Chircop M, 'The Dynamin inhibitors MiTMAB and OcTMAB induce Cytokinesis failure and inhibit cell proliferation in human cancer cells', Molecular Cancer Therapeutics, 9, 1995-2006 (2010) [C1]
DOI 10.1158/1535-7163.mct-10-0161
Citations Scopus - 6Web of Science - 3
Co-authors Adam Mccluskey
2010 Thaqi A, Scott JL, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis and biological activity of Delta-5,6-norcantharimides: Importance of the 5,6-bridge', European Journal of Medicinal Chemistry, 45, 1717-1723 (2010) [C1]
DOI 10.1016/j.ejmech.2010.01.004
Citations Scopus - 4Web of Science - 2
Co-authors Adam Mccluskey
2010 De Bock CE, Garg ML, Scott NM, Sakoff JA, Scorgie FE, Ackland S, Lincz L, 'Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo', Pharmacogenomics Journal, 1-8 (2010) [C1]
DOI 10.1038/tpj.2010.43
Citations Scopus - 20Web of Science - 17
Co-authors Stephen Ackland, Manohar Garg, Lisa Lincz
2009 Sauer B, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis of 4-substituted-3-hydroxy-5-oxo-10-oxa-4-azatricyclo[5.2.1]dec-3-yl Acetic Acid Ethyl Esters as Norcantharidin Analogues', Letters in Drug Design & Discovery, 6 1-7 (2009) [C1]
DOI 10.2174/157018009787158535
Citations Scopus - 10Web of Science - 10
Co-authors Adam Mccluskey
2009 Hill TA, Gordon CP, McGeachie AB, Venn-Brown B, Odell L, Chau N, Quan A, Mariana A, Sakoff JA, Chircop M, Robinson PJ, McCluskey A, 'Inhibition of dynamin mediated endocytosis by the dynoles-synthesis and functional activity of a family of indoles', Journal of Medicinal Chemistry, 52, 3762-3773 (2009) [C1]
DOI 10.1021/jm900036m
Citations Scopus - 1Web of Science - 7
Co-authors Adam Mccluskey
2009 Holland IP, McCluskey A, Sakoff JA, Gilbert J, Chau N, Robinson PJ, Motti CA, Wright AD, Van Altena IA, 'Steroids from an Australian Sponge Psammoclema sp', Journal of Natural Products, 72, 102-106 (2009) [C1]
DOI 10.1021/np800688f
Citations Scopus - 1Web of Science - 3
Co-authors Adam Mccluskey, Ian Vanaltena
2008 Lincz L, Mudge L-M, Scorgie FE, Sakoff JA, Hamilton C, Seldon MR, 'Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the [beta symbol] deletion variant', Neoplasia, 10 1131-1137 (2008) [C1]
DOI 10.1593/neo.08644
Citations Scopus - 49Web of Science - 45
Co-authors Lisa Lincz
2008 Hill TA, Stewart SG, Gordon CP, Ackland SP, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition', ChemMedChem: chemistry enabling drug discovery, 3, 1878-1892 (2008) [C1]
DOI 10.1002/cmdc.200800192
Citations Scopus - 6Web of Science - 4
Co-authors Adam Mccluskey, Stephen Ackland
2007 Hill T, Stewart SG, Sauer B, Gilbert J, Ackland S, Sakoff J, McCluskey A, 'Heterocyclic substituted cantharidin and norcantharidin analogues - synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity', Bioorganic and Medicinal Chemistry Letters, 17, 3392-3397 (2007) [C1]
DOI 10.1016/j.bmcl.2007.03.093
Citations Scopus - 9Web of Science - 5
Co-authors Adam Mccluskey, Stephen Ackland
2007 Hill TA, Stewart SG, Ackland S, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation', Bioorganic and Medicinal Chemistry, 15, 6126-6134 (2007) [C1]
DOI 10.1016/j.bmc.2007.06.034
Citations Scopus - 1Web of Science - 5
Co-authors Stephen Ackland, Adam Mccluskey
2007 Stewart SG, Hill TA, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity', Bioorganic and Medicinal Chemistry Letters, 15, 7301-7310 (2007) [C1]
DOI 10.1016/j.bmc.2007.08.028
Citations Scopus - 4Web of Science - 2
Co-authors Stephen Ackland, Adam Mccluskey
2005 Hill T, Sakoff JA, Robinson PJ, McCluskey A, 'Parallel Solution-Phase Synthesis of Targeted Tyrphostin Libraries with Anticancer Activity', Australian Journal of Chemistry: an international journal for chemical science, 58, 94-103 (2005) [C1]
DOI 10.1071/CH04143
Citations Scopus - 1Web of Science - 7
Co-authors Adam Mccluskey
2004 Lincz LF, Scorgie FE, Sakoff J, Fagan K, Ackland S, Enno A, 'Telomere length predicts neutrophil recovery in the absence of G-CSF after autologous peripheral blood stem cell transplantation', Bone Marrow Transplantation, 34, 439-445 (2004) [C1]
DOI 10.1038/sj.bmt.1704607
Citations Scopus - 5Web of Science - 3
Co-authors Lisa Lincz, Stephen Ackland
2004 Sakoff JA, Howitt IJ, Ackland S, McCluskey A, 'Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition', Cancer Chemotherapy and Pharmacology, 53, 225-232 (2004) [C1]
DOI 10.1007/s00280-003-0730-9
Citations Scopus - 1Web of Science - 7
Co-authors Stephen Ackland, Adam Mccluskey
2004 Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A, 'Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity', Bioorganic and Medicinal Chemistry Letters, 14, 1969-1973 (2004) [C1]
DOI 10.1016/j.bmcl.2004.01.093
Citations Scopus - 9Web of Science - 6
Co-authors Adam Mccluskey, Cecilia Russell
2004 Sakoff J, McCluskey A, 'Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents', Current Pharmaceutical Design, 10, 1139-1159 (2004) [C1]
DOI 10.2174/1381612043452686
Citations Scopus - 5Web of Science - 4
Co-authors Adam Mccluskey
2003 Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31, 68-79 (2003) [C1]
DOI 10.1016/S0045-2068(02)00524-2
Citations Scopus - 1Web of Science - 6
Co-authors Michael Bowyer, Stephen Ackland, Adam Mccluskey, Cecilia Russell
2002 McCluskey A, Sim AT, Sakoff J, 'Serine-Threonine Protein Phosphatase Inhibitors: Development of Potential Therapeutic Strategies', Journal of Medicinal Chemistry, 45, No 6, 1151-1175 (2002) [C1]
Citations Scopus - 2Web of Science - 1
Co-authors Adam Mccluskey
2002 Sakoff JA, Ackland SP, Baldwin ML, Keane MA, McCluskey A, 'Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues.', 21, 1-11 (2002) [C1]
Citations Scopus - 8Web of Science - 5
Co-authors Mirella Atherton, Adam Mccluskey, Stephen Ackland
2002 McCluskey A, Keane M, Walkom C, Bowyer M, Sim AT, Young D, Sakoff J, 'The First Two Cantharidin Analogues Displaying PP1 Selectivity', Bioorganic & Medicinal Chemistry Letters, 12, 391-393 (2002) [C1]
Citations Scopus - 5Web of Science - 3
Co-authors Mirella Atherton, Michael Bowyer, Cecilia Russell, Adam Mccluskey
2002 Garg MB, Sevester JC, Sakoff JA, Ackland SP, 'Simple liquid chromatographic method for the determination of uracil and dihydrouracil plasma levels: a potential pretreatment predictor of 5-fluorouracil toxicity', JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 774, 223-230 (2002)
DOI 10.1016/S1570-0232(02)00239-8
Citations Scopus - 5Web of Science - 3
Co-authors Stephen Ackland, Manohar Garg
2002 Sakoff J, De Waal E, Garg M, Denham J, Scorgie F, Enno A, Lincz L, Ackland S, 'Telomere Length in Haemopoietic Stem Cells can be Determined from that of Mononuclear Blood Cells or Whole Blood', Leukemia and Lymphoma, 43(10), 2017-2020 (2002) [C1]
Citations Scopus - 2Web of Science - 2
Co-authors Lisa Lincz, Manohar Garg, Stephen Ackland
2001 McCluskey A, Ackland SP, Gardiner E, Walkom CC, Sakoff JA, 'The inhibition of protein phosphatases 1 and 2A: A new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16, 291-303 (2001) [C1]
Citations Scopus - 3Web of Science - 2
Co-authors Cecilia Russell, Adam Mccluskey, Stephen Ackland
2001 McCluskey A, Walkom C, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A New Class of Modified Cantharidin Analogues Inhibiting Protein Phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters (2001), 11, 2941-2946 (2001) [C1]
Citations Scopus - 9Web of Science - 5
Co-authors Michael Bowyer, Adam Mccluskey, Stephen Ackland, Cecilia Russell
2001 McCluskey A, Sakoff JA, 'Small molecule inhibitors of serine/threonine protein phosphatases.', Mini Reviews in Medicinal Chemistry, 1, 43-55 (2001)

Serine/threonine protein phosphatases have long been ignored as potential therapeutic targets for two reasons, one the biochemical significance of these proteins has no... [more]

Serine/threonine protein phosphatases have long been ignored as potential therapeutic targets for two reasons, one the biochemical significance of these proteins has not been appreciated and two, many natural protein phosphatase inhibitors are potent toxins and are considered unsuitable for clinical use. This review outlines the biochemical role of this protein family in cancer, cystic fibrosis, immunosuppression and, cardiac and neurological disorders. Particular emphasis is also given to the synthesis of selective small molecule inhibitors and their clinical exploitation.

DOI 10.2174/1389557013407205
Citations Scopus - 66
Co-authors Adam Mccluskey
2000 McCluskey A, Keane MA, Mudgee L-M, Sim AT, Sakoff J, Quinn RJ, 'Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?', European Journal of Medicinal Chemistry, 35, 957-964 (2000) [C1]
Citations Scopus - 6Web of Science - 3
Co-authors Mirella Atherton, Adam Mccluskey
2000 Sakoff J, Ackland S, 'Thymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cells', Cancer Chemotherapy and Pharmacology, 46, 477-487 (2000) [C1]
Citations Scopus - 4Web of Science - 2
Co-authors Stephen Ackland
2000 McCluskey A, Bowyer MC, Collins E, Sim AT, Sakoff JA, Baldwin ML, 'Anhydride Modified Cantharidin Analogues: Synthesis, Inhibition of Protein Phosphatases 1 and 2A and Anticancer Activity', Bioorganic & Medicinal Chemistry Letters, 10, 1687-1690 (2000) [C1]
Citations Scopus - 9Web of Science - 7
Co-authors Michael Bowyer, Adam Mccluskey
2000 Sakoff JA, McCluskey A, Sims ATR, Stewart JF, Ackland SP, 'A counter intuitive therapy for the treatment of cancer: Inhibition of protein phosphatases 1 and 2A by cantharidin (Spanish Fly) analogues.', CLINICAL CANCER RESEARCH, 6 4495S-4495S (2000)
Co-authors Stephen Ackland, Adam Mccluskey
1996 Sakoff J, Dunstan RH, Murdoch RN, 'Uterine lipid alterations during early pseudopregnancy and following the artificial induction of decidualization by Concanavalin A in QS mice', Molecular reproductive Development, 44 93-102 (1996) [C1]
Citations Scopus - 3Web of Science - 2
1996 Sakoff JA, Murdoch RN, 'The role of calcium in the artificially induced decidual cell reaction in pseudopregnant mice', BIOCHEMICAL AND MOLECULAR MEDICINE, 57, 81-90 (1996)
DOI 10.1006/bmme.1996.0013
Citations Scopus - 8Web of Science - 8
1996 Sakoff J, Murdoch RN, 'The role of calcium ions in the Concanavalin A induced decidual cell reaction in pseudopregnant mice', Biochemical and Molecular Medicine, 57 81-90 (1996) [C1]
1996 Sakoff JA, Dunstan RH, Murdoch RN, 'Uterine lipid alterations during early pseudopregnancy and following the artificial induction of decidualization by concanavalin A in QS mice', Molecular Reproduction and Development, 44 93-102 (1996)
DOI 10.1002/(sici)1098-2795(199605)44:1&lt;93::aid-mrd11&gt;3.3.co;2-h
1995 Sakoff J, Murdoch RN, 'Uterine receptivity to the artificial deciduogenic agent, Concanavalin A in pseudopregnant', Reproduction, Fertility and Development, 7, 1095-1100 (1995) [C1]
Citations Scopus - 4Web of Science - 2
1994 Sakoff J, Murdoch RN, 'Alterations in uterine calcium ions during the induction of the decidual cell reaction in pseudopregnant mice', journal of reproduction and fertility, 101, 97-102 (1994) [C1]
Citations Scopus - 2Web of Science - 1
Show 121 more journal articles

Preprint (1 outputs)

Year Citation Altmetrics Link
2021 Legge WJ, Shimadate Y, Ghorbani M, Sakoff J, Houston TA, Kato A, et al., 'Borylated methyl cinnamates: Expedited synthesis, characterization, crystallographic analysis and biological activities in glycosidase inhibition and in cancer cells lines. (2021)
DOI 10.3762/bxiv.2021.4.v1
Edit

Grants and Funding

Summary

Number of grants 35
Total funding $3,607,747

Click on a grant title below to expand the full details for that specific grant.


20191 grants / $24,431

Establishment of an Antimicrobial Research Taskforce in NSW: NUW ART$24,431

Funding body: NUW Alliance

Funding body NUW Alliance
Project Team Cprof PETER Lewis, Associate Professor Ian Grainge, Associate Professor Karl Hassan, Professor Brett Neilan, Doctor Jennette Sakoff, Associate Professor Naresh Kumar, Professor Mike Manefield, Professor Mark Willcox, Professor Antoine van Oijen, Professor Nicholas Dixon, Associate Professor Aaron Oakley, Dr Michael Kelso
Scheme 2019 Projects
Role Investigator
Funding Start 2019
Funding Finish 2019
GNo G1801287
Type Of Funding C3100 – Aust For Profit
Category 3100
UON Y

20181 grants / $30,000

Finding new treatment options for brain tumors with DNA repair inhibitors$30,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Moira Graves, Doctor Jennette Sakoff, Doctor Michael Fay, Associate Professor Paul Tooney, Professor Nikola Bowden
Scheme Project Grant
Role Investigator
Funding Start 2018
Funding Finish 2019
GNo G1801321
Type Of Funding C3200 – Aust Not-for Profit
Category 3200
UON Y

20172 grants / $52,000

EphA2 as a circulating biomarker for GBM progression - a pilot study$27,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Doctor Michael Fay, Doctor James Lynam
Scheme Project Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1701424
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

Defining and predicting clinical toxicity in GBM patients undergoing temozolomide-radiation treatment: A multivariate study$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor James Lynam, Doctor Jennette Sakoff, Professor Jennifer Martin, Doctor Lisa Lincz, Doctor Michael Fay, Doctor Peter Galettis
Scheme Project Grant
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700586
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

20152 grants / $320,000

The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor Marjorie Walker, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Emeritus Professor John Forbes, Professor Xu Dong Zhang, Professor Pradeep Tanwar, Professor Nikola Bowden, Doctor Craig Gedye, Doctor James Lynam, Associate Professor Kelly Kiejda, Doctor Jennette Sakoff, Mr Loui Rassam, Dr Tara Roberts, Professor Soon Lee, Dr Betty Kan
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2015
Funding Finish 2018
GNo G1500825
Type Of Funding C2300 – Aust StateTerritoryLocal – Own Purpose
Category 2300
UON Y

The development of new drugs that selectively target breast cancer$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Professor Adam McCluskey
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1501381
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20142 grants / $35,000

Enhancing radiation effects for the treatment of brain cancer$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Dr JAYNE Gilbert, Professor Adam McCluskey
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301412
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

An Investigation on the Consensus Between Different Genomic and Transcriptomic Results in Breast Cancer$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Ms Heloisa Milioli, Professor Pablo Moscato, Doctor Jennette Sakoff, Professor Regina Berretta
Scheme Jennie Thomas Medical Research Travel Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1401334
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20132 grants / $233,809

The integration of bioinformatics, chemoinformatics, and toxicogenomics methods: a new approach for the identification of combination tailored therapies and novel drug targets in breast cancer$210,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor Pablo Moscato, Doctor Jennette Sakoff, Professor Regina Berretta
Scheme NSW Premier's Awards for Outstanding Cancer Research: "Big Data, Big Impact" Grant
Role Investigator
Funding Start 2013
Funding Finish 2014
GNo G1300826
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Testing parallels between placental and cancer cell proliferation and fusion: the role of transcription factories$23,809

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Dr GIAVANNA Angeli, Doctor Jorge Tolosa Gonzalez, Doctor Brett Locker, Doctor Jennette Sakoff
Scheme Research Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1301207
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20127 grants / $750,454

The Hunter Cancer Biobank (HCB): Maximising community value through validation, annotation and distribution throughout NSW$292,300

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Emeritus Professor John Forbes, Conjoint Professor Stephen Ackland, Professor Rodney Scott, Conjoint Associate Professor Barbara Young, Professor Hubert Hondermarck, Emeritus Professor Leonie Ashman, Professor Xu Dong Zhang, Associate Professor Kelly Kiejda, Professor Nikki Verrills, Doctor Jennette Sakoff, Ms Janine Lombard, Doctor Jude Weidenhofer, Professor Pradeep Tanwar
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2012
Funding Finish 2015
GNo G1200798
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

The role of clathrin in the spindle assembly checkpoint and as an anticancer target$239,760

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Ms Megan Chircop, Professor Adam McCluskey, Professor Phillip Robinson, Doctor Jennette Sakoff
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2014
GNo G1101106
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

High-Resolution Isoelectric Phosphoprotein Signalling System for Signalling Research, Biomarker Validation and Drug Development – Equipment Grant$143,394

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Hubert Hondermarck, Conjoint Professor Stephen Ackland, Doctor Lisa Lincz, Doctor Jennette Sakoff, Emeritus Professor Leonie Ashman
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200555
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Identification of a novel target for the treatment of hormone positive breast cancer$30,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Dr JAYNE Gilbert, Professor Adam McCluskey
Scheme Breast Cancer Project Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200716
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Mitotane pharmacodynamics in Adrenocortical Cancer in children and adults$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff, Ms MADHU Garg
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2013
GNo G1200319
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

The role of clathrin in the spindle assembly checkpoint and as an anticancer target$15,000

Funding body: NSW Trade & Investment

Funding body NSW Trade & Investment
Project Team Professor Adam McCluskey, Doctor Jennette Sakoff
Scheme TechVouchers Program
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1200796
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Ultrasonic Homogenizer System and -80 ºC Freezers for chemical and biological sample storage$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Adam McCluskey, Professor Eileen McLaughlin, Cprof PETER Lewis, Ms Belinda Nixon, Doctor Shaun Roman, Doctor Jennette Sakoff, Associate Professor Ian Grainge
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100986
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20115 grants / $1,610,603

Priority Research Centre for Cancer$555,811

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Conjoint Professor Stephen Ackland, Professor Xu Dong Zhang, Emeritus Professor John Forbes, Emeritus Professor Leonie Ashman, Professor Nikola Bowden, Professor Gordon Burns, Conjoint Professor Jim Denham, Professor Hubert Hondermarck, Doctor Lisa Lincz, Doctor Jennette Sakoff, Professor Peter Stanwell, Doctor Rick Thorne, Professor Nikki Verrills
Scheme Priority Research Centre
Role Investigator
Funding Start 2011
Funding Finish 2016
GNo G1101013
Type Of Funding Internal
Category INTE
UON Y

Development of pthaladyn-based dynamin I-selective inhibitors for treatment of epilepsy$544,831

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Adam McCluskey, Professor Phillip Robinson, Professor Terence O'Brien, Ms Megan Chircop, Doctor Jennette Sakoff
Scheme Development Grants
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo G1000740
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Chemical Biology$444,961

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Doctor Warwick Belcher, Associate Professor Ian Grainge, Professor Christopher Grof, Cprof PETER Lewis, Professor Eileen McLaughlin, Doctor Shaun Roman, Emeritus Professor Ray Rose, Doctor Jennette Sakoff, Professor Nikki Verrills
Scheme Priority Research Centre
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo G1100052
Type Of Funding Internal
Category INTE
UON Y

Computational prediction and functional clarification of novel drug combination strategies for the treatment of brain tumors$50,000

Funding body: Maitland Cancer Appeal Committee Incorporated

Funding body Maitland Cancer Appeal Committee Incorporated
Project Team Professor Pablo Moscato, Doctor Dan Johnstone, Professor Regina Berretta, Doctor Luke Mathieson, Professor Manuel Graeber, Doctor Jennette Sakoff
Scheme Research Funding
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100275
Type Of Funding C3300 – Aust Philanthropy
Category 3300
UON Y

Eppendorf mastercycler pro with thermomixer comfort and 5430R centrifuge$15,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Eileen McLaughlin, Cprof PETER Lewis, Professor Adam McCluskey, Conjoint Professor Keith Jones, Professor Brett Nixon, Doctor Shaun Roman, Doctor Jennette Sakoff, Associate Professor Ian Grainge, Doctor Janet Bristow, Doctor Xiao Yang
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100028
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20101 grants / $35,000

New small molecules for the treatment of neuroblastoma$35,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Dr JAYNE Gilbert, Doctor Jennette Sakoff, Ms Megan Chircop
Scheme Paediatric Oncology Project Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G0900192
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20072 grants / $352,000

FACSAria - Fluorescence activated cell sorter$300,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor Nikki Verrills, Emeritus Professor Leonie Ashman, Distinguished Emeritus Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
Scheme Research Infrastructure Grants
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0187666
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

HMRI Contribution toward FACSAria - Fluorescence activated cell sorter$52,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Nikki Verrills, Emeritus Professor Leonie Ashman, Distinguished Emeritus Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188207
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20061 grants / $11,000

Overcoming radiation resistance in malignant melanoma$11,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lisa Lincz, Doctor Jennette Sakoff
Scheme Project Grant
Role Investigator
Funding Start 2006
Funding Finish 2007
GNo G0186528
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20031 grants / $50,000

High Pressure and Fluorous Approaches to fostriecin libraries: New Therapeutic Opportunities.$50,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Professor Adam McCluskey, Assoc. Prof David Young, Doctor Jennette Sakoff
Scheme Discovery Projects
Role Investigator
Funding Start 2003
Funding Finish 2003
GNo G0182117
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

20021 grants / $10,000

New targets for chemotherapy: anti-cancer drugs that target protein phosphatases$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Adam McCluskey, Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff
Scheme Project Grant
Role Investigator
Funding Start 2002
Funding Finish 2002
GNo G0181459
Type Of Funding Internal
Category INTE
UON Y

20013 grants / $23,450

Synergistic interaction between thymidylate synthase and protein phosphatase inhibition in colon cancer cells$10,450

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Doctor Jennette Sakoff
Scheme Early Career Researcher Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo G0181233
Type Of Funding Internal
Category INTE
UON Y

Predicting bone marrow regeneration in cancer patients through the use of telomere quantitative (Q)-FISH$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lisa Lincz, Doctor Jennette Sakoff
Scheme Lions Club of Stroud
Role Investigator
Funding Start 2001
Funding Finish 2001
GNo G0181502
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Pulse Education Prize for 2001$3,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff
Scheme Research Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo G0181503
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

20003 grants / $45,000

Influence of Haematopoetic stem cell telorase activity on bone marrow recovery following myoablative therapy.$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Lisa Lincz, Ms Kerry Fagan, Doctor Jennette Sakoff
Scheme Research Grant
Role Investigator
Funding Start 2000
Funding Finish 2000
GNo G0180171
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

A counter-intuitive anticancer treatment.$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff
Scheme Research Grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo G0180205
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Young Medical Researcher of the Year.$5,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff
Scheme Research Grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo G0180182
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

19991 grants / $25,000

Selective Inhibitors of Protein Phosphatases as Anti-cancer agents$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Doctor Jennette Sakoff, Professor Adam McCluskey, Conjoint Professor Stephen Ackland
Scheme Research Grant
Role Lead
Funding Start 1999
Funding Finish 1999
GNo G0178390
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y
Edit

Research Supervision

Number of supervisions

Completed2
Current0

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2020 PhD Design and Synthesis of Arylhydrocarbon Receptor Ligands for the Treatment of Breast Cancer PhD (Chemistry), College of Engineering, Science and Environment, The University of Newcastle Co-Supervisor
2017 PhD Breast Cancer Intrinsic Subtypes: A Critical Conception in Bioinformatics PhD (Biological Sciences), College of Engineering, Science and Environment, The University of Newcastle Co-Supervisor
Edit

Dr Jennette Sakoff

Position

Conjoint Associate Professor
Experimental Therapeutics Group
School of Environmental and Life Sciences
College of Engineering, Science and Environment

Focus area

Chemistry

Contact Details

Email jennette.sakoff@newcastle.edu.au
Phone 0240143560
Edit